TLR2 and TLR4 Mediate Differential Responses to Limb Ischemia through MyD88-Dependent and Independent Pathways

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Sachdev, Ulka ^b   Cui, Xiangdong ^b   McEnaney, Ryan ^b   Wang, Tian ^b   Benabou, Kelly ^b   Tzeng, Edith ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CELL PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; SMOOTH MUSCLE ACTIN; TIR DOMAIN CONTAINING ADAPTER INDUCING BETA INTERFERON; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; EX VIVO STUDY; FAT REPLACEMENT; FEMORAL ARTERY; HISTOLOGY; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LASER DOPPLER PERFUSION IMAGING; LIMB ISCHEMIA; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; MUSCLE NECROSIS; MUSCLE PROTECTION; MUSCLE REGENERATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTECTION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; HINDLIMB; HUMANS; ISCHEMIA; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SKELETAL; MYELOID DIFFERENTIATION FACTOR 88; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 84870496387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050654     Document Type: Article

References (34)

1. Marston WA, Davies SW, Armstrong B, Farber MA, Mendes RC, et al. (2006) Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg 44: 108-114.
2. Buschmann I, Schaper W, (2000) The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 190: 338-342.
3. Messina LM, Brevetti LS, Chang DS, Paek R, Sarkar R, (2002) Therapeutic angiogenesis for critical limb ischemia: invited commentary. J Control Release 78: 285-294.
4. Yla-Herttuala S, Alitalo K, (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701.
5. Kajiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, et al. (2007) Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 71: 196-201.
6. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
7. Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH, (2004) Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med 9: 193-198.
8. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, et al. (2006) Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 17: 683-691.
9. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, et al. (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90: 966-973.
10. Cho SW, Moon SH, Lee SH, Kang SW, Kim J, et al. (2007) Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. Circulation 116: 2409-2419.
11. Semenza GL, (2000) Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106: 809-812.
12. Jain RK, (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693.
13. Lawall H, Bramlage P, Amann B, (2011) Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 53: 445-453.
14. Lotze MT, Tracey KJ, (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342.
15. Yang H, Wang H, Czura CJ, Tracey KJ, (2005) The cytokine activity of HMGB1. J Leukoc Biol 78: 1-8.
16. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-5560.
17. Sachdev U, Cui X, Hong G, Namkoong S, Karlsson JM, et al. (2012) High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. Journal of Vascular Surgery 55: 180-191.
18. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, et al. (2007) High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212.
19. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, et al. (2005) Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 102: 13141-13146.
20. Charge SB, Rudnicki MA, (2004) Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209-238.
21. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, et al. (2005) Overexpression of Dimethylarginine Dimethylaminohydrolase Reduces Tissue Asymmetric Dimethylarginine Levels and Enhances Angiogenesis. Circulation 111: 1431-1438.
22. Chang C-H, Lai L-C, Cheng H-C, Chen K-R, Syue Y-Z, et al. (2011) TBK1-associated Protein in Endolysosomes (TAPE) Is an Innate Immune Regulator Modulating the TLR3 and TLR4 Signaling Pathways. Journal of Biological Chemistry 286: 7043-7051.
23. Isenberg JS, (2004) Nitric oxide modulation of early angiogenesis. Microsurgery 24: 385-391.
24. Frantz S, Vincent KA, Feron O, Kelly RA, (2005) Innate immunity and angiogenesis. Circ Res 96: 15-26.
25. Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, et al. (2003) Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol 163: 253-259.
26. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, et al. (2004) The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
27. Pinhal-Enfield G, Ramanathan M, Hasko G, Vogel SN, Salzman AL, et al. (2003) An Angiogenic Switch in Macrophages Involving Synergy between Toll-Like Receptors 2, 4, 7, and 9 and Adenosine A2A Receptors. The American Journal of Pathology 163: 711-721.
28. Kagan JC, Medzhitov R, (2006) Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125: 943-955.
29. Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, et al. (2007) TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol 178: 6252-6258.
30. Hua F, Ha T, Ma J, Gao X, Kelley J, et al. (2005) Blocking the MyD88-dependent pathway protects the myocardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys Res Commun 338: 1118-1125.
31. Li Y, Xiang M, Yuan Y, Xiao G, Zhang J, et al. (2009) Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. American Journal of Physiology- Regulatory, Integrative and Comparative Physiology 297: R1670-R1680.
32. Mathes AL, Lafyatis R, (2011) Role for Toll-like receptor 3 in muscle regeneration after cardiotoxin injury. Muscle Nerve 43: 733-740.
33. Egginton S, Hudlická O, (1999) Early changes in performance, blood flow and capillary fine structure in rat fast muscles induced by electrical stimulation. The Journal of Physiology 515: 265-275.
34. West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, et al. (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467: 972-976.